Fibrobiologics Inc
FBLG
NASDAQ
Biotechnology
$1.06
USD
-0.09 (-7.83%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $7.66M
Volume 177.0K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-18.14M
TTM
-37.2%
YoY
Operating Cash Flow
$-14.79M
TTM
+1.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.4 | 2.2 | 1.8 | 2.1 | 2.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 4.5 | 5.0 | 2.6 | 5.1 | 4.0 |
Operating Income | -4.5 | -5.0 | -2.6 | -5.1 | -4.0 |
EBITDA | -4.4 | -5.0 | -1.9 | -5.0 | -4.0 |
Other Income / Expense | -0.2 | -0.8 | -0.5 | 0.1 | -0.1 |
Total Other Income / Expense | -0.2 | -0.7 | -0.7 | 0.1 | -0.1 |
Income Before Income Taxes | -4.7 | -5.8 | -3.2 | -5.0 | -4.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -4.7 | -5.8 | -3.2 | -5.0 | -4.1 |
Consolidated Net Income / Loss | -4.7 | -5.8 | -3.2 | -5.0 | -4.1 |
Net Income Attributable to Common Shareholders | -4.7 | -5.8 | -3.2 | -5.0 | -4.1 |
Basic EPS | -$2.41 | -$2.60 | -$1.08 | -$1.33 | -$0.66 |
Diluted EPS | -$2.41 | -$2.60 | -$1.08 | -$1.33 | -$0.66 |
Basic Shares Outstanding | 1.9M | 2.2M | 3.0M | 3.8M | 6.3M |
Diluted Shares Outstanding | 1.9M | 2.2M | 3.0M | 3.8M | 6.3M |